29 results about "Diagnostic biomarker" patented technology

The application relates to a blood biomarker for evaluating and diagnosing Parkinson's disease and an application thereof. The blood biomarker is SERPINA3 and / or alpha-Syn. By using the biomarker as a diagnostic biomarker for Parkinson's disease, early diagnosis of Parkinson's disease can be assisted by detecting the SERPINA3 level and the alpha-Syn level in a blood sample, the trauma is small, the operation is simple, and the method is suitable for most patients and has high patient acceptance; and the SERPINA3 and alpha-Syn levels in the blood sample can be determined by a photochemical luminescence detection method, the detection sensitivity is high, the accuracy is high, and early, efficient and high-precision diagnosis of Parkinson's disease can be realized.

This invention discloses the application of ESCO1 and NUFIP2 in the diagnosis and treatment of pancreatic cancer, relating to the field of biomedical technology. This invention provides the application of ESCO1 and / or NUFIP2 as pancreatic cancer biomarkers in the preparation of pancreatic cancer diagnostic or prognostic assessment products, and also provides the application of ESCO1 and / or NUFIP2 as drug targets in the screening or preparation of drugs for the prevention and / or treatment of pancreatic cancer. This invention discovers that ESCO1 and NUFIP2 have important biological significance in pancreatic cancer, with NUFIP2 expression regulated by ESCO1, and both expression levels positively correlated with the malignant progression of pancreatic cancer. Therefore, ESCO1 and NUFIP2 can not only serve as potential diagnostic biomarkers and therapeutic targets for pancreatic cancer, but also provide new theoretical basis and research directions for optimizing pancreatic cancer immunotherapy strategies.

The application discloses a circRNA detection method based on Argonaute protein and rolling circle amplification. The method comprises the following steps: mixing a sample containing target circRNA to be detected with a specific reverse transcription primer and reverse transcriptase to obtain long-chain cDNA; mixing the obtained long-chain cDNA with pfAgo, gDNA and a DNA nucleic acid probe to carry out a reaction, and calculating the content of the target circRNA according to the fluorescence signal of the reaction mixture; the nucleotide sequence of the gDNA is specifically complementary to the cDNA sequence obtained by reverse transcription of the circRNA; the sequence of the DNA nucleic acid probe is specifically complementary to the sequence of the cDNA after one cutting of the cDNA by the pfAgo; and the DNA nucleic acid probe is a single-stranded DNA probe with a fluorescent label. The application can realize high-sensitivity, high-specificity and multiple target simultaneous analysis and detection of potential diagnostic biomarkers of liver cancer such as hsa_circ_0001445 and hsa_circ_0001141.

The application discloses an axSpA diagnosis biomarker combination and application thereof in judging axSpA diagnosis effect, relates to the biomedical field, and comprises the following four plasma proteins: LIM and SH3 domain protein 1 (LASP1), calponin binding protein 2 (CNN2), neuron protein kinase C and tyrosine protein kinase substrate 2 (PACSIN2) and tropomyosin 4 (TPM4). The expression levels of the four proteins in the plasma of axSpA light / severe group patients are all up-regulated relative to a healthy control group, and there is a significant difference between the severe group and the light group. Through deep proteomics, multi-algorithm statistics, machine learning models and independent queue immunological verification, the protein combination composed of LASP1, CNN2, PACSIN2 and TPM4 is first systematically identified and verified as an excellent performance of axSpA diagnosis biomarker.

This invention belongs to the field of biomedical technology, specifically relating to the application of plasma exosome biomarkers in the diagnosis and early warning of diabetic bladder dysfunction. This invention pioneered the use of 4D-DIA proteomics technology to conduct a comprehensive differential analysis of plasma exosome proteins from patients with diabetic bladder dysfunction (DBD). It successfully identified protein components with significantly different expression levels in the plasma exosomes of DBD patients, demonstrating significant value as potential diagnostic biomarkers. This invention is the first to propose that the detection of a four-protein combination in plasma exosomes (FCGR3B+THBS1+HLA-F+ATP5PB) can serve as a biomarker for diabetic bladder dysfunction (DBD) and also as an early warning indicator for the disease. This protein combination achieved an overall accuracy of 83.3% in identifying DBD.

This invention relates to the field of biomedical technology and discloses a biomarker for diagnosing polycystic ovary syndrome (PCOS) and its application. The diagnostic biomarker is circSPECC1(4), which is formed by reverse splicing and circularization of the fourth exon of the SPECCC1 gene. It has a length of 1580 nt and possesses a closed circular RNA structure. circSPECC1(4) is specifically highly expressed in ovarian granulosa cells of PCOS patients, and there is no significant difference in the mRNA expression level of its parent gene SPECCC1. circSPECC1(4) possesses RNase R nuclease resistance stability and is mainly located in the cytoplasm. Knocking down the expression of circSPECC1(4) can significantly promote apoptosis of ovarian granulosa cells and arrest the ovarian granulosa cell cycle at the G0 / G1 phase. This invention clearly demonstrates that circSPECC1(4) can serve as a specific diagnostic biomarker for PCOS, fully verifying the structural characteristics, expression specificity, and pathological regulatory function of this circular RNA, filling the gap in the existing field of PCOS diagnosis which lacks highly specific and stable molecular diagnostic targets.

The application belongs to the technical field of molecular diagnosis, and particularly relates to extracellular vesicle lncRNA as a molecular marker for diagnosing heart failure combined with dilated cardiomyopathy. The molecular marker is NR_045681, and the specific nucleic acid sequence of the extracellular vesicle lncRNA is shown in SEQ ID NO. 5. The technical scheme provided by the application effectively improves the detection accuracy of heart failure combined with dilated cardiomyopathy. The P value of the combination of the molecular marker is less than 0.05, the |log fold change (FC)| is greater than 1, and the molecular marker has obvious differential expression relative to a healthy control group.

The application discloses application of ferritin-carrying neuron-derived extracellular vesicles in auxiliary diagnosis of Parkinson's disease and belongs to the field of biomedical technology. The application realizes effective identification of specific ferritin-carrying neuron-derived extracellular vesicles in a flow cytometer by fluorescence labeling of L1 cell adhesion molecule antibodies and ferritin heavy chain antibodies, and can accurately distinguish PD patients, MSA patients and healthy people by analyzing the concentration of the ferritin-carrying neuron-derived extracellular vesicles in blood plasma, thereby providing an efficient PD diagnosis biomarker and greatly improving the ability of early diagnosis of PD and identification of MSA and PD, and effectively solving the problems of complexity and low sensitivity faced by traditional diagnosis methods.

The application provides a diagnostic biomarker for identifying IgG4-related pancreatitis and pancreatic cancer and an application thereof, and the diagnostic biomarker is used in the preparation of a detection reagent for diagnosing IgG4-related pancreatitis and pancreatic cancer. By detecting the diagnostic biomarker, it can be identified whether it is IgG4-related pancreatitis or pancreatic cancer, and the operation is convenient, practical, and has good application value.

This invention relates to the pharmaceutical applications of MRPS7 as a diagnostic biomarker for non-small cell lung cancer (NSCLC) and its inhibitors, belonging to the field of biomedical technology. For the first time, this invention utilizes immunohistochemical analysis of tumor tissues from NSCLC patients and paired adjacent normal tissues to confirm that MRPS7 protein is significantly overexpressed in NSCLC tissues (p<0.001), and this difference is statistically significant in both lung adenocarcinoma and lung squamous cell carcinoma subtypes. Furthermore, this invention demonstrates through in vitro functional experiments that knocking down MRPS7 gene expression using siRNA targeting MRPS7 significantly inhibits the proliferation, migration, and invasion abilities of NSCLC cells (A549, SK-MES-1) (p<0.001). Therefore, reagents for detecting MRPS7 expression levels can be used to prepare NSCLC diagnostic products, and MRPS7 inhibitors can be used to prepare drugs for treating NSCLC. This invention provides a novel molecular biomarker for the diagnosis of NSCLC and a new strategy for targeted therapy of NSCLC.

The application discloses a biomarker related to bladder cancer and application thereof, the biomarker is tRF-1:28-chrM.Ser-TGA and / or tiRNA-1:34-Glu-CTC-1-M2, which can be used for preparing a bladder cancer early high-risk patient diagnosis and / or prognosis evaluation product, and belongs to the technical field of biological medicine. The biomarker is screened through RNA sequencing, has higher sensitivity and specificity as a biomarker, and is verified through qRT-PCR and ROC curve analysis, and it is proved that tRF-1:28-chrM.Ser-TGA and tiRNA-1:34-Glu-CTC-1-M2 can excellently distinguish bladder cancer patients from normal people, and can be used as an early diagnostic biomarker and a new treatment target of bladder cancer patients, which has great clinical value and practical significance for early clinical diagnosis of bladder cancer, related treatment target evaluation and improvement of the survival rate of patients.

The application discloses a diabetic nephropathy diagnosis biomarker and application thereof, and belongs to the field of in-vitro diagnosis, wherein the diabetic nephropathy diagnosis biomarker is a combination of 8-hydroxydeoxyguanosine and nitrate; the concentration of 8-hydroxydeoxyguanosine and nitrate in urine can be detected by a double-antibody enzyme-linked immunoassay and a nitric oxide analyzer respectively, and then a diabetic nephropathy diagnosis scheme based on the two biomarkers is constructed; the scheme has the advantages of non-invasiveness and high specificity, can accurately distinguish diabetic nephropathy from diabetes, and provides a new strategy for early screening and diagnosis of diabetic nephropathy.

The present invention provides methods for using drain fluid obtained from medical procedures to assess diagnostic biomarkers indicative of disease obtained from drain fluid. In some embodiments, the diagnostics biomarkers are cell-free nucleic acids. In some embodiments, the disease is cancer. In some embodiments, a library of cfDNA is prepared and / or sequenced. In some embodiments, the methods comprise extracting nucleic acid from surgical drain fluid; conducting a size selection procedure to isolate cell-free nucleic acid from the surgical drain fluid; and detecting the cell-free nucleic acid.

This invention discloses the application of UFSP2 in the auxiliary diagnosis or treatment of prostate cancer, belonging to the field of biomedical technology. Experimental verification revealed that UFSP2 can serve as a diagnostic biomarker for prostate cancer and also possesses the potential to predict biochemical recurrence. Furthermore, this invention found that inhibiting UFSP2 expression significantly enhances the proliferation, migration, and colony formation capabilities of cells; upregulating UFSP2 expression significantly inhibits these capabilities, indicating that UFSP2 can serve as a therapeutic target for prostate cancer. Further, upregulating UFSP2 expression can also enhance the sensitivity of cancer cells to the chemotherapy drug docetaxel, suggesting that enhancing UFSP2 helps improve the therapeutic effect of chemotherapy drugs on prostate cancer. In summary, this invention provides a new biomarker for the diagnosis of prostate cancer and offers new targets and approaches for its treatment.

Disclosed is an application of sBCMA as a biomarker in cerebrospinal fluid in diagnosis and monitoring of antibody-mediated central nervous system autoimmune diseases. Taking NMOSD as an example, the level of sBCMA in cerebrospinal fluid of NMOSD patients is significantly higher than that of control subjects matched for age and gender, and there is a positive correlation between the level of sBCMA in cerebrospinal fluid and a nerve injury-related index NFL, a blood-cerebrospinal fluid barrier breakdown-related index QAlb, or a neuroinflammation-related index sTREM2 in cerebrospinal fluid of NMOSD patients. This indicates that the level of sBCMA in cerebrospinal fluid can be used as a biomarker for the diagnosis of antibody-mediated central nervous system autoimmune diseases such as NMOSD and the evaluation of the severity of nerve injuries, the degree of damage to blood-cerebrospinal fluid barrier, and the level of neuroinflammation in patients.

This invention provides the application of FAM205A in the preparation of a male infertility detection kit, detecting FAM205A gene abnormalities and / or abnormal FAM205A protein expression levels. By integrating proteomics analysis, functional validation, and a gene knockout mouse model, this invention demonstrates that FAM205A deficiency disrupts sperm morphology, spermatogenesis, motility, and fertilization capacity through a dual mechanism, making FAM205A a reliable diagnostic biomarker for idiopathic male infertility. FAM205A gene abnormalities can be detected through whole-genome sequencing, and abnormal FAM205A protein expression levels can be detected using antibodies that specifically bind to the FAM205A protein, leading to the development of a male infertility detection kit.

This invention relates to a gene diagnostic biomarker and kit for diagnosing refractory gastroesophageal reflux disease (GERD), belonging to the field of biomedical technology. The invention provides the application of a biomarker, NRF1 and / or NRF2, in the preparation of a diagnostic reagent for refractory GERD; a diagnostic reagent for diagnosing GERD, comprising reagents for detecting NRF1 and / or NRF2 expression; a diagnostic kit for diagnosing GERD, comprising reagents for detecting NRF1 and / or NRF2 expression; and the application of the reagent for detecting NRF1 and / or NRF2 expression in the preparation of a diagnostic reagent for refractory GERD, comprising primers for detecting NRF1 and / or NRF2 expression. This invention provides a reliable tool for the rapid and accurate diagnosis of refractory GERD.

The application discloses a biomarker of calcific aortic valve disease and application thereof, and belongs to the technical field of biological medicine. In the application, through non-targeted metabolomics discovery, serotonin deficiency can be a novel independent biomarker of calcific aortic valve stenosis. Specifically, receiver operating characteristic curve analysis shows that serotonin has good diagnostic efficiency for CAVD, and the optimal cutoff value is 148.2 ng / mL. Therefore, it is found in the application that the level of serotonin in CAVD patients is reduced, and the reduction is irrelevant to the severity of the disease, indicating that the serotonin has the potential to serve as a diagnostic biomarker.

This invention provides the application of the ApoL1 gene as a diagnostic biomarker for acute myocardial infarction (AMI), belonging to the field of gene function and application. By detecting the expression levels of APOL1 protein and mRNA in peripheral blood of AMI patients and healthy individuals, it was found that the expression level of APOL1 protein in the AMI group was 1.41 times that in the healthy group, and the APOL1 mRNA level in the AMI group was 1.25 times that in the healthy group. Compared with healthy individuals, the mRNA and protein levels of APOL1 in AMI patients were significantly increased, demonstrating that high APOL1 expression is an independent risk factor for AMI and can serve as one of the biomarkers for predicting AMI.

This invention discloses a biomarker, kit, and application for the early diagnosis of type 1 diabetes. The biomarker is CTLA4 protein and KLRD1 protein, both of which originate from the same CD4 group. + CD8 + Extracellular vesicles of double-positive T cells were analyzed, and a kit was prepared to detect CTLA4 and KLRD1 proteins for early diagnosis of type 1 diabetes. This invention screens and identifies CD4... + CD8 + The CTLA4 and KLRD1 proteins carried in the extracellular vesicles of double-positive T cells serve as early diagnostic biomarkers for type 1 diabetes, which has significant scientific and clinical value for early screening of type 1 diabetes.

This invention provides the use of VSTM1 expression levels or the degree of oxidation modification of its ligand Galectin-1, or the degree of interaction between the two, in the diagnosis of active SLE. This invention verified by flow cytometry that neutrophil ROS levels are increased in SLE patients, and that SLE patient serum significantly promotes increased neutrophil ROS formation and cell death. In neutrophils of active SLE patients, VSTM1 expression levels at both mRNA and protein levels were significantly lower than in healthy controls. Simultaneously, the binding of VSTM1 to its serum ligand Galectin-1 inhibited neutrophil ROS formation and cell death. In active SLE patients, the binding degree of VSTM1 to Galectin-1 was significantly reduced. The degree of Galectin-1 oxidation in SLE serum was higher than in healthy controls, and oxidized Galectin-1 could not bind to the receptor VSTM1, resulting in increased neutrophil ROS and cell death. These results indicate that the expression of receptor VSTM1, the oxidation of ligand Galectin-1, and the binding of receptor VSTM1 and ligand Galectin-1 can all serve as diagnostic markers for patients with active SLE.

This invention discloses the application of ZBTB7A as a target in the preparation of products for the diagnosis or treatment of sepsis-associated encephalopathy (SAE), belonging to the field of biomedical technology. This invention confirms that ZBTB7A can serve as a diagnostic biomarker and therapeutic target for SAE, providing strong technical support for the early diagnosis and treatment of SAE. Clinical sample validation shows that the expression level of ZBTB7A in peripheral blood astrocyte-derived exosomes of SAE patients is significantly downregulated, enabling early, non-invasive auxiliary diagnosis of SAE with high clinical diagnostic efficacy. This invention clarifies that high expression of ZBTB7A can effectively inhibit the release of pro-inflammatory factors, reduce lipid peroxidation and iron overload, improve the structural and functional integrity of mitochondria, protect neuronal and synaptic structures, and significantly reverse cognitive impairment.

This patent application describes miRNAs in the diagnosis of small fiber neuropathy (SFN) and miRNAs as therapeutic agents for small fiber neuropathy (SFN).

This invention discloses the application of the antigenic peptide EG16 and its antibody in the preparation of diagnostic products for rheumatoid arthritis (RA), belonging to the field of disease diagnostic technology. This invention aims to address the problem of the lack of highly sensitive and specific serological diagnostic biomarkers for RA (especially early-stage RA). The amino acid sequence of the antigenic peptide EG16 is APKRIRLPHIREDDQP or BSA-C-APKRIRLPHIREDDQP. The RA diagnostic product is used to detect the content of epitope antibodies that specifically bind to the aforementioned antigenic peptide EG16 in patient biological samples. The expression level of this epitope antibody in RA patients is significantly higher than that in healthy individuals and other patients with easily confused rheumatic immune diseases, with a diagnostic sensitivity of 43.43% and a specificity of 92.80%, and a sensitivity of 44.44% in preclinical RA patients. This provides a novel, highly specific auxiliary diagnostic indicator for RA (especially in its early stages).

This invention relates to the field of molecular diagnostics, disclosing a gene composition, kit, and its application for the early diagnosis of papillary renal cell carcinoma (pRCC). It provides a non-invasive and highly accurate diagnostic biomarker for pRCC, achieving a sensitivity, specificity, and accuracy of 86.05%, 90.51%, and 88.79%, respectively, demonstrating excellent clinical diagnostic performance and effectively addressing the problem of low accuracy in pRCC diagnosis. This invention also provides a kit for the combined detection of DNA methylation levels of the ZNF154, OXR1, TMEM178A, and LINE1 genes, which is simple to operate and has stable performance.

This invention discloses the application of Sjögren's syndrome biomarkers in products for diagnosing Sjögren's syndrome and a method for constructing a diagnostic model for Sjögren's syndrome, relating to the field of Sjögren's syndrome diagnostic technology. The Sjögren's syndrome biomarker includes the Val to Phe ratio. The diagnostic model established based on this single biomarker has an AUC value greater than 0.9 on its ROC curve, exhibiting extremely high diagnostic specificity, sensitivity, and accuracy. Combinations of this biomarker with other biomarkers also demonstrate extremely high diagnostic efficacy. Therefore, the Sjögren's syndrome diagnostic biomarkers provided by this invention have promising application prospects in the diagnosis of Sjögren's syndrome.

This invention discloses a biomarker for detecting placenta accreta, namely the MI R323B gene. Reduced expression of MI R323B in subject samples is an indicator of placenta accreta. Furthermore, the application of MI R323B as a diagnostic biomarker for placenta accreta in the preparation of reagents for diagnosing placenta accreta is disclosed. Results show that the MI R323B gene expression level is downregulated in PAS patients, with high diagnostic accuracy. MI R323B plays an important role in the diagnosis and treatment of placenta accreta and can be used to prepare drugs for treating placenta accreta or related diseases.